Qulab
Qulab automates research and development for chemical and pharmaceutical companies to accelerate small-molecule drug discovery. It combines computational chemistry, artificial intelligence, and quantum computing with laboratory automation to design and evaluate candidate molecules. The company operates as a computational drug discovery platform serving pharma and chemical R&D teams. Qulab's approach reduces manual iteration in medicinal chemistry by integrating simulation, machine learning, and quantum-enabled modeling. The technology targets industry-scale drug discovery workflows and preclinical candidate generation.
Qulab
Qulab automates research and development for chemical and pharmaceutical companies to accelerate small-molecule drug discovery. It combines computational chemistry, artificial intelligence, and quantum computing with laboratory automation to design and evaluate candidate molecules. The company operates as a computational drug discovery platform serving pharma and chemical R&D teams. Qulab's approach reduces manual iteration in medicinal chemistry by integrating simulation, machine learning, and quantum-enabled modeling. The technology targets industry-scale drug discovery workflows and preclinical candidate generation.
TL;DR
What they do: Automates small-molecule drug discovery using computational chemistry, AI, quantum computing, and lab automation
Founded: 2017
HQ: Los Angeles, California, United States
Founder / CEO: Alireza Shabani
Industry: Biotechnology
Company Overview
Problem Domain
Small-molecule drug discovery and preclinical candidate generation for pharmaceutical and chemical R&D.
Founded
2017
Industry
Biotechnology
Funding Track Record
Public profiles indicate dated rounds in 2018, 2019, 2021 but amounts are not disclosed in the provided evidence
Investor Signal
“Amidi Group, Brooks Hill Partners, Civilization Ventures, Cota Capital, Newchip Accelerator, Plug and Play, Prefix Capital, Rising Tide, Start Capital”